$ABCL
AbCellera Biologics Inc.

2023 Q3 Form 10-Q Financial Statement

#000170305723000022 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $6.599M $10.06M $45.92M
YoY Change -93.49% -78.1% 66.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.84M $19.36M $17.53M
YoY Change 5.66% 10.44% 40.28%
% of Gross Profit
Research & Development $37.92M $36.47M $26.69M
YoY Change 42.64% 36.68% 77.36%
% of Gross Profit
Depreciation & Amortization $3.100M $5.610M $4.897M
YoY Change 24.0% 14.56% 345.18%
% of Gross Profit
Operating Expenses $61.49M $61.45M $54.31M
YoY Change -3.39% 13.13% 56.63%
Operating Profit -$54.89M -$51.39M -$8.396M
YoY Change -245.46% 512.07%
Interest Expense $10.70M $10.78M
YoY Change
% of Operating Profit
Other Income/Expense, Net $15.61M $2.606M $1.510M
YoY Change 76.39% 72.58% -59.84%
Pretax Income -$39.28M -$38.00M -$6.886M
YoY Change -184.31% 451.9% 232.18%
Income Tax -$10.67M -$7.476M -$101.0K
% Of Pretax Income
Net Earnings -$28.61M -$30.53M -$6.785M
YoY Change -207.46% 349.93% 192.08%
Net Earnings / Revenue -433.55% -303.58% -14.78%
Basic Earnings Per Share -$0.10 -$0.11 -$0.02
Diluted Earnings Per Share -$0.10 -$0.11 -$23.83K
COMMON SHARES
Basic Shares Outstanding 289.4M shares 288.7M shares 284.5M
Diluted Shares Outstanding 289.5M shares 288.9M shares 284.7M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $785.8M $179.7M $790.6M
YoY Change 111.25% -77.26% -0.25%
Cash & Equivalents $172.4M $179.7M $790.6M
Short-Term Investments $613.4M $615.9M $231.7M
Other Short-Term Assets $71.23M $47.36M $68.89M
YoY Change 53.19% -31.25% 952.25%
Inventory $1.200M $1.447M
Prepaid Expenses
Receivables $37.40M $661.6M $284.4M
Other Receivables $38.10M $40.55M $0.00
Total Short-Term Assets $919.5M $930.7M $1.144B
YoY Change -12.06% -18.64% 32.4%
LONG-TERM ASSETS
Property, Plant & Equipment $277.2M $259.6M $149.2M
YoY Change 38.19% 74.05% 70.53%
Goodwill $47.81M $47.81M
YoY Change 0.0%
Intangibles $124.1M $126.7M
YoY Change -12.96%
Long-Term Investments $62.90M $58.79M $65.82M
YoY Change -5.72% -10.68% 54.14%
Other Assets $80.69M $113.4M $43.84M
YoY Change 64.46% 158.76% 174.92%
Total Long-Term Assets $592.7M $606.4M $449.8M
YoY Change 16.96% 34.81% 56.27%
TOTAL ASSETS
Total Short-Term Assets $919.5M $930.7M $1.144B
Total Long-Term Assets $592.7M $606.4M $449.8M
Total Assets $1.512B $1.537B $1.594B
YoY Change -2.59% -3.55% 38.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.40M $21.03M $10.31M
YoY Change 86.72% 103.87% 84.0%
Accrued Expenses $11.90M $5.953M $4.023M
YoY Change 47.97% 81.22%
Deferred Revenue $17.51M $8.542M
YoY Change 156.9%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $110.2M $118.9M $221.1M
YoY Change 3.95% -46.23% 217.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $5.051M $190.3M $125.2M
YoY Change 76.79% 52.0% 7454.13%
Total Long-Term Liabilities $219.2M $190.3M $125.2M
YoY Change 11.72% 52.0% 9.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $110.2M $118.9M $221.1M
Total Long-Term Liabilities $219.2M $190.3M $125.2M
Total Liabilities $329.4M $342.3M $380.9M
YoY Change 8.99% -10.13% 106.83%
SHAREHOLDERS EQUITY
Retained Earnings $326.9M $355.5M
YoY Change -28.32%
Common Stock $857.3M $841.2M
YoY Change 7.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.183B $1.195B $1.213B
YoY Change
Total Liabilities & Shareholders Equity $1.512B $1.537B $1.594B
YoY Change -2.59% -3.55% 38.37%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$28.61M -$30.53M -$6.785M
YoY Change -207.46% 349.93% 192.08%
Depreciation, Depletion And Amortization $3.100M $5.610M $4.897M
YoY Change 24.0% 14.56% 345.18%
Cash From Operating Activities -$100.0K $19.90M $273.0M
YoY Change -99.92% -92.71% 73.09%
INVESTING ACTIVITIES
Capital Expenditures $20.90M $27.20M -$31.32M
YoY Change -244.01% -186.84% -15.0%
Acquisitions
YoY Change
Other Investing Activities $8.100M -$7.189M $4.125M
YoY Change -103.03% -274.28% -146.75%
Cash From Investing Activities -$12.80M -$34.39M -$27.20M
YoY Change -95.46% 26.45% -40.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.600M 419.0K 1.173M
YoY Change -34836.84% -64.28% -122.92%
NET CHANGE
Cash From Operating Activities -100.0K 19.90M 273.0M
Cash From Investing Activities -12.80M -34.39M -27.20M
Cash From Financing Activities 6.600M 419.0K 1.173M
Net Change In Cash -6.300M -14.07M 247.0M
YoY Change -98.46% -105.7% 130.97%
FREE CASH FLOW
Cash From Operating Activities -$100.0K $19.90M $273.0M
Capital Expenditures $20.90M $27.20M -$31.32M
Free Cash Flow -$21.00M -$7.298M $304.3M
YoY Change -81.3% -102.4% 56.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 abcl Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised
StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised
403000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12291000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
507000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
168573000 usd
us-gaap Profit Loss
ProfitLoss
161788000 usd
us-gaap Profit Loss
ProfitLoss
-70638000 usd
us-gaap Depreciation
Depreciation
3681000 usd
us-gaap Depreciation
Depreciation
5810000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5213000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5314000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2120000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3252000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
24404000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
31873000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
298000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4429000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
6963000 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
24269000 usd
abcl Increase Decrease In Accrued Royalties Receivable
IncreaseDecreaseInAccruedRoyaltiesReceivable
-106583000 usd
abcl Increase Decrease In Accrued Royalties Receivable
IncreaseDecreaseInAccruedRoyaltiesReceivable
-9260000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
52251000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
22884000 usd
abcl Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable
-1882000 usd
abcl Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable
-2827000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2979000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4870000 usd
us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
28049000 usd
us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
-16253000 usd
abcl Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
-5406000 usd
abcl Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
-25566000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4139000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4833000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
373234000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24160000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45817000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42185000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
134306000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
528891000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
145808000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
422814000 usd
abcl Proceeds From Receipt Of Grant Funding
ProceedsFromReceiptOfGrantFunding
8098000 usd
abcl Proceeds From Receipt Of Grant Funding
ProceedsFromReceiptOfGrantFunding
7693000 usd
abcl Payments To Acquire Long Term Investments And Other Assets
PaymentsToAcquireLongTermInvestmentsAndOtherAssets
11657000 usd
abcl Payments To Acquire Long Term Investments And Other Assets
PaymentsToAcquireLongTermInvestmentsAndOtherAssets
36757000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
15694000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
6673000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53568000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-183999000 usd
abcl Repayment Of Liability For In Licensing Agreement And Contingent Consideration
RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration
4133000 usd
abcl Repayment Of Liability For In Licensing Agreement And Contingent Consideration
RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration
677000 usd
abcl Proceeds From Debt And Exercise Of Stock Options
ProceedsFromDebtAndExerciseOfStockOptions
2175000 usd
abcl Proceeds From Debt And Exercise Of Stock Options
ProceedsFromDebtAndExerciseOfStockOptions
638000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
316297000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
501142000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
414651000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1824000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2290000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
815615000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
204747000 usd
abcl Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable
NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable
2146000 usd
abcl Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable
NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable
11718000 usd
abcl Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation
NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation
796000 usd
abcl Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation
NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation
2945000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of operationsAbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together.
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</span></div>
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30528000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
161788000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70638000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
288905587 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
284292312 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6785000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-30528000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
161788000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-70638000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
284686542 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
288905587 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
284292312 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
288357081 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29068871 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
284686542 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
288905587 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
313361183 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
288357081 shares
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
48678673 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11937411 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50707389 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50775907 shares
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
235730000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
283847000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18475000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24207000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
217255000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
259640000 usd
CY2022Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
25600000 usd
CY2023Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
56400000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
0 usd
CY2023Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
10500000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
2300000 usd
us-gaap Depreciation
Depreciation
3700000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
3000000 usd
us-gaap Depreciation
Depreciation
5800000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
155143000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
28396000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
126747000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
9059000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4297000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4297000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4297000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
4297000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26247000 usd
abcl Number Of Joint Ventures
NumberOfJointVentures
2 jointventure
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
64817000 usd
CY2022Q4 abcl Prepaid Expense And Other Current
PrepaidExpenseAndOtherCurrent
9064000 usd
CY2022Q4 abcl Materials And Supplies Current
MaterialsAndSuppliesCurrent
1532000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
75413000 usd
CY2022Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0 usd
CY2023Q2 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
17400000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14780000 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21025000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5583000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5953000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6454000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3859000 usd
CY2022Q4 abcl Deferred Grant Funding Current
DeferredGrantFundingCurrent
6285000 usd
CY2023Q2 abcl Deferred Grant Funding Current
DeferredGrantFundingCurrent
6521000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
48000 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
15037000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
33150000 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
52395000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12113000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16399000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24404000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31873000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
34954000 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32004000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41128000 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36258000 usd
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
6300000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7700000 usd
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4000000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
8100000 usd
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
32300000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
18500000 usd
CY2022Q2 us-gaap Royalty Expense
RoyaltyExpense
5200000 usd
us-gaap Royalty Expense
RoyaltyExpense
49800000 usd
us-gaap Royalty Expense
RoyaltyExpense
0 usd
CY2023Q2 us-gaap Royalty Expense
RoyaltyExpense
0 usd
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001703057-23-000022-index-headers.html Edgar Link pending
0001703057-23-000022-index.html Edgar Link pending
0001703057-23-000022.txt Edgar Link pending
0001703057-23-000022-xbrl.zip Edgar Link pending
abcellera813-8197inalcon.htm Edgar Link pending
abcellera813-8197inalcon001.jpg Edgar Link pending
abcellera813-8197inalcon002.jpg Edgar Link pending
abcellera813-8197inalcon003.jpg Edgar Link pending
abcellera813-8197inalcon004.jpg Edgar Link pending
abcellera813-8197inalcon005.jpg Edgar Link pending
abcellera813-8197inalcon006.jpg Edgar Link pending
abcellera813-8197inalcon007.jpg Edgar Link pending
abcellera813-8197inalcon008.jpg Edgar Link pending
abcellera813-8197inalcon009.jpg Edgar Link pending
abcellera813-8197inalcon010.jpg Edgar Link pending
abcellera813-8197inalcon011.jpg Edgar Link pending
abcellera813-8197inalcon012.jpg Edgar Link pending
abcellera813-8197inalcon013.jpg Edgar Link pending
abcellera813-8197inalcon014.jpg Edgar Link pending
abcellera813-8197inalcon015.jpg Edgar Link pending
abcellera813-8197inalcon016.jpg Edgar Link pending
abcellera813-8197inalcon017.jpg Edgar Link pending
abcellera813-8197inalcon018.jpg Edgar Link pending
abcellera813-8197inalcon019.jpg Edgar Link pending
abcellera813-8197inalcon020.jpg Edgar Link pending
abcellera813-8197inalcon021.jpg Edgar Link pending
abcellera813-8197inalcon022.jpg Edgar Link pending
abcellera813-8197inalcon023.jpg Edgar Link pending
abcellera813-8197inalcon024.jpg Edgar Link pending
abcellera813-8197inalcon025.jpg Edgar Link pending
abcellera813-8197inalcon026.jpg Edgar Link pending
abcellera813-8197inalcon027.jpg Edgar Link pending
abcellera813-8197inalcon028.jpg Edgar Link pending
abcellera813-8197inalcon029.jpg Edgar Link pending
abcellera813-8197inalcon030.jpg Edgar Link pending
abcellera813-8197inalcon031.jpg Edgar Link pending
abcellera813-8197inalcon032.jpg Edgar Link pending
abcellera813-8197inalcon033.jpg Edgar Link pending
abcellera813-8197inalcon034.jpg Edgar Link pending
abcellera813-8197inalcon035.jpg Edgar Link pending
abcellera813-8197inalcon036.jpg Edgar Link pending
abcellera813-8197inalcon037.jpg Edgar Link pending
abcellera813-8197inalcon038.jpg Edgar Link pending
abcellera813-8197inalcon039.jpg Edgar Link pending
abcellera813-8197inalcon040.jpg Edgar Link pending
abcellera813-8197inalcon041.jpg Edgar Link pending
abcellera813-8197inalcon042.jpg Edgar Link pending
abcellera813-8197inalcon043.jpg Edgar Link pending
abcellera813-8197inalcon044.jpg Edgar Link pending
abcellera813-8197inalcon045.jpg Edgar Link pending
abcellera813-8197inalcon046.jpg Edgar Link pending
abcellera813-8197inalcon047.jpg Edgar Link pending
abcellera813-8197inalcon048.jpg Edgar Link pending
abcellera813-8197inalcon049.jpg Edgar Link pending
abcellera813-8197inalcon050.jpg Edgar Link pending
abcellera813-8197inalcon051.jpg Edgar Link pending
abcellera813-8197inalcon052.jpg Edgar Link pending
abcellera813-8197inalcon053.jpg Edgar Link pending
abcellera813-8197inalcon054.jpg Edgar Link pending
abcellera813-8197inalcon055.jpg Edgar Link pending
abcellera813-8197inalcon056.jpg Edgar Link pending
abcellera813-8197inalcon057.jpg Edgar Link pending
abcellera813-8197inalcon058.jpg Edgar Link pending
abcellera813-8197inalcon059.jpg Edgar Link pending
abcellera813-8197inalcon060.jpg Edgar Link pending
abcellera813-8197inalcon061.jpg Edgar Link pending
abcellera813-8197inalcon062.jpg Edgar Link pending
abcellera813-8197inalcon063.jpg Edgar Link pending
abcellera813-8197inalcon064.jpg Edgar Link pending
abcellera813-8197inalcon065.jpg Edgar Link pending
abcellera813-8197inalcon066.jpg Edgar Link pending
abcellera813-8197inalcon067.jpg Edgar Link pending
abcellera813-8197inalcon068.jpg Edgar Link pending
abcellera813-8197inalcon069.jpg Edgar Link pending
abcellera813-8197inalcon070.jpg Edgar Link pending
abcellera813-8197inalcon071.jpg Edgar Link pending
abcellera813-8197inalcon072.jpg Edgar Link pending
abcellerabccontributiona.htm Edgar Link pending
abcellerabccontributiona001.jpg Edgar Link pending
abcellerabccontributiona002.jpg Edgar Link pending
abcellerabccontributiona003.jpg Edgar Link pending
abcellerabccontributiona004.jpg Edgar Link pending
abcellerabccontributiona005.jpg Edgar Link pending
abcellerabccontributiona006.jpg Edgar Link pending
abcellerabccontributiona007.jpg Edgar Link pending
abcellerabccontributiona008.jpg Edgar Link pending
abcellerabccontributiona009.jpg Edgar Link pending
abcellerabccontributiona010.jpg Edgar Link pending
abcellerabccontributiona011.jpg Edgar Link pending
abcellerabccontributiona012.jpg Edgar Link pending
abcellerabccontributiona013.jpg Edgar Link pending
abcellerabccontributiona014.jpg Edgar Link pending
abcellerabccontributiona015.jpg Edgar Link pending
abcellerabccontributiona016.jpg Edgar Link pending
abcellerabccontributiona017.jpg Edgar Link pending
abcellerabccontributiona018.jpg Edgar Link pending
abcellerabccontributiona019.jpg Edgar Link pending
abcellerabccontributiona020.jpg Edgar Link pending
abcellerabccontributiona021.jpg Edgar Link pending
abcellerabccontributiona022.jpg Edgar Link pending
abcellerabccontributiona023.jpg Edgar Link pending
abcellerabccontributiona024.jpg Edgar Link pending
abcellerabccontributiona025.jpg Edgar Link pending
abcellerabccontributiona026.jpg Edgar Link pending
abcellerabccontributiona027.jpg Edgar Link pending
abcellerabccontributiona028.jpg Edgar Link pending
abcellerabccontributiona029.jpg Edgar Link pending
abcellerabccontributiona030.jpg Edgar Link pending
abcellerabccontributiona031.jpg Edgar Link pending
abcellerabccontributiona032.jpg Edgar Link pending
abcellerabccontributiona033.jpg Edgar Link pending
abcellerabccontributiona034.jpg Edgar Link pending
abcellerabccontributiona035.jpg Edgar Link pending
abcellerabccontributiona036.jpg Edgar Link pending
abcellerabccontributiona037.jpg Edgar Link pending
abcellerabccontributiona038.jpg Edgar Link pending
abcellerabccontributiona039.jpg Edgar Link pending
abcellerabccontributiona040.jpg Edgar Link pending
abcellerabccontributiona041.jpg Edgar Link pending
abcellerabccontributiona042.jpg Edgar Link pending
abcellerabccontributiona043.jpg Edgar Link pending
abcellerabccontributiona044.jpg Edgar Link pending
abcellerabccontributiona045.jpg Edgar Link pending
abcellerabccontributiona046.jpg Edgar Link pending
abcellerabccontributiona047.jpg Edgar Link pending
abcellerabccontributiona048.jpg Edgar Link pending
abcellerabccontributiona049.jpg Edgar Link pending
abcellerabccontributiona050.jpg Edgar Link pending
abcellerabccontributiona051.jpg Edgar Link pending
abcellerabccontributiona052.jpg Edgar Link pending
abcellerabccontributiona053.jpg Edgar Link pending
abcellerabccontributiona054.jpg Edgar Link pending
abcellerabccontributiona055.jpg Edgar Link pending
abcl-20230630.htm Edgar Link pending
abcl-20230630.xsd Edgar Link pending
abcl-20230630xexx311.htm Edgar Link pending
abcl-20230630xexx312.htm Edgar Link pending
abcl-20230630xexx321.htm Edgar Link pending
abcl-20230630xexx322.htm Edgar Link pending
abcl-20230630_g1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
abcl-20230630_lab.xml Edgar Link unprocessable
abcl-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
abcl-20230630_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
abcl-20230630_def.xml Edgar Link unprocessable
abcl-20230630_cal.xml Edgar Link unprocessable